Search Within
Applied Filters:
Showing 1-30 of 117 results for "


" within Papers
Sophie J Bakri et al.
Expert opinion on pharmacotherapy, 5(1), 195-203 (2003-12-19)
This article reviews the pharmacotherapeutics of verteporfin (Visudyne), Novartis Pharma AG) used in ocular photodynamic therapy. The chemistry, pharmacokinetics and pharmacodynamics of the drug are reviewed. The article highlights and summarises the results of the multi-centre, randomised, controlled clinical trials...
L El Matri et al.
Journal francais d'ophtalmologie, 36(1), 29-34 (2012-12-15)
To compare the long-term safety and of intravitreal bevacizumab injections (IVB) and verteporferin photodynamic therapy (PDT) in the treatment of choroidal neovascularization (CNV) in high myopia. Review of retrospectively collected data of 60 eyes of 60 patients with high myopic...
Paul Rundle
The British journal of ophthalmology, 98(4), 494-497 (2014-01-28)
To report on the use of multi-dose photodynamic therapy (PDT) in the treatment of posterior uveal melanoma. Prospective case series. 18 patients with posterior uveal melanoma were treated with a minimum of three sessions of PDT. Mean tumour thickness was...
Perspectives on verteporfin therapy combined with intravitreal corticosteroids.
Ursula Schmidt-Erfurth et al.
Archives of ophthalmology (Chicago, Ill. : 1960), 124(4), 561-563 (2006-04-12)
YAP1 and AR interactions contribute to the switch from androgen-dependent to castration-resistant growth in prostate cancer.
Kuser-Abali G, et al.
Nature Communications, 6, 8126-8126 (2015)
Eva Smretschnig et al.
Retina (Philadelphia, Pa.), 33(2), 316-323 (2013-01-15)
To evaluate the results of indocyanine green angiography (ICGA)-guided verteporfin (Visudyne®; Novartis Pharma, Switzerland) photodynamic therapy (PDT) with half-fluence rate in the treatment of chronic central serous chorioretinopathy. A retrospective review was conducted of 20 eyes of 19 consecutive patients...
Victor C K Lo et al.
Journal of orthopaedic research : official publication of the Orthopaedic Research Society, 31(9), 1398-1405 (2013-04-30)
Photodynamic therapy (PDT) has been shown to ablate tumors within vertebral bone and yield short-term improvements in vertebral architecture and biomechanical strength, in particular when combined with bisphosphonate (BP) treatment. Longer-term outcomes of PDT combined with current treatments for skeletal...
João Pinheiro-Costa et al.
Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde, 232(3), 149-155 (2014-09-10)
To compare outcomes after switching from intravitreal ranibizumab to bevacizumab in neovascular age-related macular degeneration (AMD). A retrospective review of 110 eyes treated in a 1+PRN (pro re nata) clinical setting with ranibizumab that were switched to bevacizumab. Patients analyzed...
S H Lim et al.
Eye (London, England), 27(3), 353-362 (2013-03-02)
The purpose of this study is to determine the efficacy of half-fluence photodynamic therapy (PDT) depending on the degree of hyperfluorescence based on indocyanine green angiography (ICGA) for treatment of chronic central serous chorioretinopathy (CSC). We conducted a prospective study...
Ioannis Datseris et al.
Seminars in ophthalmology, 30(2), 112-117 (2013-10-15)
To evaluate combination treatment with reduced-fluence photodynamic therapy (RDPDT) with Verteporfin and intravitreal bevacizumab, compared to bevacizumab alone, for choroidal neovascularization (CNV) in age-related macular degeneration. This was a prospective, randomized comparative study comprising 95 patients with CNV. 49 patients...
Tadatoshi Sato et al.
Nature communications, 11(1), 3282-3282 (2020-07-03)
Osteocytes, cells ensconced within mineralized bone matrix, are the primary skeletal mechanosensors. Osteocytes sense mechanical cues by changes in fluid flow shear stress (FFSS) across their dendritic projections. Loading-induced reductions of osteocytic Sclerostin (encoded by Sost) expression stimulates new bone...
Chia-Lin Wu et al.
Clinical science (London, England : 1979), 134(13), 1593-1612 (2020-06-20)
Transcriptional co-activator with PDZ-binding motif (TAZ) is a key downstream effector of the Hippo tumor-suppressor pathway. The functions of TAZ in the kidney, especially in tubular epithelial cells, are not well-known. To elucidate the adaptive expression, protective effects on kidney...
Elena Enzo et al.
The EMBO journal, 34(10), 1349-1370 (2015-03-23)
Increased glucose metabolism and reprogramming toward aerobic glycolysis are a hallmark of cancer cells, meeting their metabolic needs for sustained cell proliferation. Metabolic reprogramming is usually considered as a downstream consequence of tumor development and oncogene activation; growing evidence indicates...
Stefan Hagen et al.
Retina (Philadelphia, Pa.), 35(2), 223-230 (2014-08-08)
To evaluate short-wavelength FAF as a parameter of retinal pigment epithelium function in eyes with acute symptomatic central serous chorioretinopathy after indocyanine green angiography-guided verteporfin photodynamic therapy with half-fluence rate. A retrospective review over a period of 1 year of...
Rufino M Silva et al.
Retina (Philadelphia, Pa.), 33(2), 309-315 (2012-10-26)
To evaluate the efficacy and safety of standard photodynamic therapy with verteporfin at 48 months in patients with chronic central serous chorioretinopathy. A retrospective, multicenter, interventional case series analysis in patients with chronic central serous chorioretinopathy, treated with standard photodynamic...
Debadrita Bhattacharya et al.
Developmental cell, 53(2), 199-211 (2020-04-04)
The Warburg effect is one of the metabolic hallmarks of cancer cells, characterized by enhanced glycolysis even under aerobic conditions. This physiological adaptation is associated with metastasis , but we still have a superficial understanding of how it affects cellular...
D Vysloužilová et al.
Ceska a slovenska oftalmologie : casopis Ceske oftalmologicke spolecnosti a Slovenske oftalmologicke spolecnosti, 68(4), 131-134 (2012-12-12)
The aim of this study was to evaluate efficiency and long-term stabilization effect in patients with classic type of myopic choroidal neovascular membrane (CNV), treated with photodynamic therapy (PDT) with verteporfin (Visudyne - Novartis AG, Basel, Switzerland). We have verified...
Xiuquan Ma et al.
Nature communications, 10(1), 296-296 (2019-01-19)
Despite significant progress, our understanding of how specific oncogenes transform cells is still limited and likely underestimates the complexity of downstream signalling events. To address this gap, we use mass spectrometry-based chemical proteomics to characterize the global impact of an...
P K Kaiser
Current medical research and opinion, 23(3), 477-487 (2007-03-16)
To discuss the rationale for combining anti-angiogenic treatment with verteporfin (Visudyne) photodynamic therapy in the management of choroidal neovascularization (CNV) due to age-related macular degeneration (AMD) and evaluate available evidence for the therapeutic benefits of such approaches. The Medline and...
Alan F Cruess et al.
Acta ophthalmologica, 87(2), 118-132 (2008-06-26)
Photodynamic therapy (PDT) with verteporfin has been used less comprehensively in the treatment of exudative age-related macular degeneration (AMD), and specifically of choroidal neovascularization (CNV), since the advent of antiangiogenic therapies. Recently, there has been a renewed interest in PDT...
Yukari Mae et al.
Molecular and clinical oncology, 13(3), 10-10 (2020-08-06)
Photodynamic therapy (PDT) induces photochemical reactions, resulting in the destruction of tumor cells via singlet (S1) oxygen production. This cellular destruction occurs specifically in tumor cells, following selective accumulation of a photosensitizer and its excitation by a specific wavelength. Verteporfin...
A J Augustin et al.
European journal of ophthalmology, 16(6), 824-834 (2006-12-28)
Choroidal neovascularization associated with age-related macular degeneration is the primary cause of blindness in the elderly in developed countries, due to a number of pathogenic effects, including angiogenesis, cell-mediated inflammation, leukocyte adhesion and extravasation, and matrix remodeling. By producing photochemical...
Martin Sin et al.
Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia, 158(1), 138-143 (2012-11-08)
To evaluate photodynamic therapy (PDT) combined with the preferential the cyclooxygenase-2 (COX-2) inhibitor, nabumetone in the treatment of the neovascular age-related macular degeneration (ARMD). A prospective, double-blind, randomized study on 60 patients with subfoveal CNV secondary to ARMD without any...
G Huber et al.
Seminars in ophthalmology, 16(4), 213-217 (2004-10-30)
The potential for photodynamic therapy to provide new treatment options for patients with choroidal neovascularization has been of interest to ophthalmologists for many years. Verteporfin (Visudyne, Novartis AG) is the first photodynamic drug to receive regulatory approval for use in...
Markus Ritter et al.
The British journal of ophthalmology, 98(12), 1629-1635 (2014-08-01)
To investigate the impact of antiangiogenic monotherapy and photodynamic therapy (PDT) as add-on strategy on retinal morphology, and to analyse prognostic biomarkers for visual outcome and retreatment frequency in neovascular age-related macular degeneration (nAMD). 255 patients participating in the MONT...
Saki Manabe et al.
American journal of ophthalmology, 159(4), 644-651 (2015-01-18)
To evaluate macular choroidal thickness after reduced-fluence photodynamic therapy (PDT) for chronic central serous chorioretinopathy (CSC). Prospective, consecutive, interventional case series. Twenty-two eyes with chronic CSC were treated with reduced-fluence PDT. Macular choroidal thickness was examined using spectral-domain optical coherence...
W Rahman et al.
Journal francais d'ophtalmologie, 36(3), e37-e40 (2012-12-04)
We describe a rare case of bilateral circumscribed choroidal haemangioma in an otherwise healthy male, which mimicked chronic central serous chorioretinopathy (CSCR). A 52-year-old Asian man presented with a one-year history of visual decline in his left eye. The vision...
Caroline Fenton et al.
Drugs & aging, 23(5), 421-445 (2006-07-11)
Photodynamic therapy (PDT) with verteporfin (Visudyne), a photosensitising protoporphyrin derivative, is used in the management of subfoveal choroidal neovascularisation (CNV) secondary to age-related macular degeneration (AMD) or pathological myopia (PM). PDT with verteporfin over 1 and 2 years reduces the...
Retina (Philadelphia, Pa.), 25(2), 119-134 (2005-02-04)
Guidelines originally were published in 2002 based on best available scientific data as well as consensus of expert opinion in the absence of controlled clinical trial data to assist ophthalmologists with selection of patients for whom photodynamic therapy with verteporfin...
Zhuzhu Li et al.
Cancer letters, 339(1), 128-134 (2013-07-23)
Vascular-targeted photodynamic therapy (vPDT) is a novel vascular targeting modality based on site-directed delivery of a photosensitizer to tumor vasculature, which induces reactive oxygen species (ROS)-mediated vascular effects upon light activation. To enhance the therapeutic outcome of vPDT, we combined...
Page 1 of 4
Page 1 of 4